| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1370425 | Bioorganic & Medicinal Chemistry Letters | 2011 | 4 Pages |
As the best-characterized ubiquitin-like protein (UBL), small ubiquitin-related modifier (SUMO) was found to conjugate with a number of proteins to regulate cellular functions including transcription, signal transduction, and cell cycle. While E1, E2 and E3 ligases are responsible for the forward SUMOylation reaction, SUMO-specific proteases (SENPs) reversibly remove SUMO from the SUMOylated proteins. Recently, SENP1 was found to be a potential therapeutic target for the treatment of prostate cancers, but the design and synthesis of its inhibitors have not been reported. We designed and synthesized a series of benzodiazepine-based SENP1 inhibitors, and they showed inhibitory activity as good as IC50 = 9.2 μM (compound 38). The structure–activity relationship was also discussed.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
